Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KMT2A | Q03164 | 2/20 | 0.46 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.41 |
| ▸ | CASP3 | P42574 | 4/20 | 0.40 |
| ▸ | OPRD1 | P41143 | 1/20 | 0.38 |
| ▸ | MDM4 | O15151 | 1/20 | 0.36 |
| ▸ | TP53 | P04637 | 1/20 | 0.36 |
| ▸ | FABP7 | O15540 | 1/20 | 0.35 |
| ▸ | FABP5 | Q01469 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1595033 | 0.82 | KMT2A (0.52) | KMT2AEPHX2CASP3MDM4TP53 | |
| SCHEMBL16453926 | 0.78 | KMT2A (0.54) | KMT2AEPHX2CASP3OPRD1MDM4 | |
| SCHEMBL892879 | 0.78 | KMT2A (0.44) | KMT2AEPHX2CASP3OPRD1MDM4 | |
| SCHEMBL6239792 | 0.76 | KMT2A (0.49) | KMT2AEPHX2CASP3MDM4TP53 | |
| SCHEMBL16140731 | 0.75 | KMT2A (0.63) | KMT2AEPHX2CASP3OPRD1FABP7 | |
| SCHEMBL30697177 | 0.75 | KMT2A (0.63) | KMT2AEPHX2CASP3OPRD1FABP7 | |
| SCHEMBL13010967 | 0.75 | MDM4 (0.48) | KMT2AEPHX2CASP3MDM4TP53 | |
| SCHEMBL13984381 | 0.75 | MDM4 (0.48) | KMT2AEPHX2CASP3MDM4TP53 | |
| SCHEMBL17830013 | 0.75 | MDM4 (0.48) | KMT2AEPHX2CASP3MDM4TP53 | |
| SCHEMBL21320276 | 0.75 | KMT2A (0.58) | KMT2AEPHX2CASP3MDM4TP53 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2018115309-A1 | PREPARATION OF SUGAR-NUCLEOTIDES | NOVO NORDISK A/S (DK) | 2018-06-28 | — | — | WO | disclosed |
| US-8841439-B2 | Nucleotide sugar purification using membranes | NOVO NORDISK A/S (DK) | 2014-09-23 | — | — | US | disclosed |
| US-20120083600-A1 | NUCLEOTIDE SUGAR PURIFICATION USING MEMBRANES | NOVO NORDISK A/S (DK) | 2012-04-05 | — | — | US | disclosed |
| US-20090048440-A1 | Nucleotide Sugar Purification Using Membranes | NEOSE TECHNOLOGIES, INC. (US) | 2009-02-19 | — | — | US | disclosed |
| WO-2007056191-A2 | NUCLEOTIDE SUGAR PURIFICATION USING MEMBRANES | NEOSE TECHNOLOGIES, INC. (US) | 2007-05-18 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120083600-A1 | NUCLEOTIDE SUGAR PURIFICATION USING MEMBRANES | SLC35B2, SLC35A1, GALNT1 | KMT2A 3014/4885EPHX2 3834/4885CASP3 4800/4885 |
| US-20090048440-A1 | Nucleotide Sugar Purification Using Membranes | SLC35B2, SLC35A1, GALNT1 | KMT2A 3014/4885EPHX2 3834/4885CASP3 4800/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.